Wang Qianrong, Tang Xiangning, Wang Yu, Zhang Danyi, Li Xia, Liu Shanshan
National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
Department of endocrinology, the Second Affiliated Hospital of University of South China, 421001 Hunan Province, China.
J Adv Res. 2025 Mar;69:157-168. doi: 10.1016/j.jare.2024.03.009. Epub 2024 Mar 15.
Non-alcoholic steatohepatitis (NASH), an emerging global healthcare problem, has become the leading cause of liver transplantation in recent decades. No effective therapies in the clinic have been proven due to the incomplete understanding of the pathogenesis of NASH, and further studies are expected to continue to delve into the mechanisms of NASH. Extracellular vesicles (EVs), which are small lipid membrane vesicles carrying proteins, microRNAs and other molecules, have been identified to play a vital role in cell-to-cell communication and are involved in the development and progression of various diseases. In recent years, there has been increasing interest in the role of EVs in NASH. Many studies have revealed that EVs mediate important pathological processes in NASH, and the role of EVs in NASH is distinct and variable depending on their origin cells and target cells. This review outlines the emerging mechanisms of EVs in the development of NASH and the preclinical evidence related to stem cell-derived EVs as a potential therapeutic strategy for NASH. Moreover, possible strategies involving EVs as clinical diagnostic, staging and prognostic biomarkers for NASH are summarized.
非酒精性脂肪性肝炎(NASH)是一个新出现的全球性医疗问题,在近几十年已成为肝移植的主要原因。由于对NASH发病机制的认识不完整,临床上尚未证实有有效的治疗方法,预计进一步的研究将继续深入探究NASH的机制。细胞外囊泡(EVs)是携带蛋白质、微小RNA和其他分子的小脂质膜囊泡,已被确定在细胞间通讯中起重要作用,并参与各种疾病的发生和发展。近年来,人们对EVs在NASH中的作用越来越感兴趣。许多研究表明,EVs介导NASH中的重要病理过程,并且EVs在NASH中的作用因其来源细胞和靶细胞而不同且多变。本综述概述了EVs在NASH发生发展中的新机制以及与干细胞衍生的EVs作为NASH潜在治疗策略相关的临床前证据。此外,总结了涉及EVs作为NASH临床诊断、分期和预后生物标志物的可能策略。